단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
    2.
    发明公开
    단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물 有权
    2,7-取代的噻吩并[3,2-D]吡啶化合物作为蛋白激酶抑制剂

    公开(公告)号:KR1020110044053A

    公开(公告)日:2011-04-28

    申请号:KR1020090100867

    申请日:2009-10-22

    CPC classification number: C07D495/04 C07D519/00

    Abstract: PURPOSE: A 2,7-substituted thieno[3,2-d]pyrimidine compound is provided to ensure excellent effect of suppressing various protein kinases and to prevent and treat abnormal cell growth diseases. CONSTITUTION: A 2,7-substituted thieno[3,2-d]pyrimidine compound is denoted by chemical formula 1. A pharmaceutical composition contains the compound of chemical formula 1 as an active ingredient. The pharmaceutical composition is used for preventing and treating abnormal cell growth diseases through ALK, Aurora A, EphA1, FAK, Flt3, Fms, Itk, KDR, Kit, Met, Ret, Src, Syk, Tie2, or TrkB protein kinase suppression mechanism. An agent for preventing and treating tumor contains the compound of chemical formula 1 as an active ingredient.

    Abstract translation: 目的:提供2,7-取代的噻吩并[3,2-d]嘧啶化合物,以确保抑制各种蛋白激酶和预防和治疗异常细胞生长疾病的优异效果。 构成:2,7-取代的噻吩并[3,2-d]嘧啶化合物由化学式1表示。药物组合物含有化学式1的化合物作为活性成分。 该药物组合物用于通过ALK,Aurora A,EphA1,FAK,Flt3,Fms,Itk,KDR,Kit,Met,Ret,Src,Syk,Tie2或TrkB蛋白激酶抑制机制预防和治疗异常细胞生长疾病。 用于预防和治疗肿瘤的药物含有化学式1的化合物作为活性成分。

    단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
    3.
    发明公开
    단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물 有权
    新颖的1,6-二取代吲哚化合物作为蛋白激酶抑制剂

    公开(公告)号:KR1020110045688A

    公开(公告)日:2011-05-04

    申请号:KR1020090102359

    申请日:2009-10-27

    Abstract: PURPOSE: A 1,6-substituted indole compound with an activity of suppressing protein kinase is provided to prevent and treat tumor caused by protein kinase. CONSTITUTION: A 1,6-substituted indole compound is denoted by chemical formula 1. A pharmaceutical composition contains the 1,6-subsituted indole compound as an active ingredient. The pharmaceutical composition is used for preventing and treating tumor disease caused by mechanism of protein kinase of Raf, KDR, Fms, Tie2, SAPK2a, Ret, Abl, Abl(T315I), ALK, Aurora A, Bmx, Src, EphA1, FGFR, Flt3, Itk, JAK2, Met, PDGFR, Plk, Ret, Syk, or Trk.

    Abstract translation: 目的:提供具有抑制蛋白激酶活性的1,6-取代吲哚化合物,以预防和治疗由蛋白激酶引起的肿瘤。 构成:1,6-取代的吲哚化合物由化学式1表示。药物组合物含有1,6-取代的吲哚化合物作为活性成分。 该药物组合物用于预防和治疗由Raf,KDR,Fms,Tie2,SAPK2a,Ret,Abl,Abl(T315I),ALK,Aurora A,Bmx,Src,EphA1,FGFR等蛋白激酶的机制引起的肿瘤疾病, Flt3,Itk,JAK2,Met,PDGFR,Plk,Ret,Syk或Trk。

Patent Agency Ranking